Press kit.

Across 200 publicly-listed Janoshik Analytical lab tests submitted to vialaudit's mirror, the median purity is 99.7%. That figure understates the underlying problem rather than refuting it. Vendors decide which batches to publish. Failed lots are systematically excluded from the public listings — the public corpus is a curated best-of, not a representative sample.

The implication for buyers and regulators: the headline pass rate circulating in the niche (99%+) and the much lower 43% pass rate referenced in the only large-scale industry survey (Finnrick's 7,164-test review) are both correct. They measure different populations. A clean public-test record is a necessary signal of vendor quality, not a sufficient one.

Of the eight vendors vialaudit currently audits — five active, three shut down in the past 12 months — none appear in the Janoshik public listing under their own vendor identifiers, even when their suppliers do. The data the buyer can verify and the data the buyer wants to verify rarely overlap. That gap is what the audit cycle exists to close.

“Most peptide vendor reviews online are sponsored placements dressed up as opinions. We built the alternative — a public dataset of vendor lab results plus the tools to query it. The first surprising finding is how much the public data systematically excludes.”

“The 99.7% median purity in our public-test mirror isn't evidence the market is clean. It's evidence vendors only publish the batches they expect to pass. Both can be true at once.”

“Buyers should treat any vendor COA as one input, not a verdict. The publishing decisions tell you more than the test result does.”

Attribution: vialaudit editorial desk. Individual contributors write under pen names for operational reasons; see /authors for the contributor masthead.

Each angle below has a published vialaudit article that documents the underlying claim with sources.

• Self-selection bias quantified. What 7,164 Janoshik tests reveal about peptide vendor purity — analysis of the public-test corpus and what it does and doesn't prove.
• The data warned before regulators acted. Three vendors closed in 12 months — what the COA data showed before they did — predictive patterns in pre-shutdown lab data.
• Compounding-pharmacy GLP-1 access is closing. 503A and the PCAC: how compounding restrictions reshaped the legal GLP-1 market — regulatory timeline buyers are still confused about.
• FDA enforcement is accelerating. FDA peptide enforcement, 2024–2026: a chronological reading — every public action against compounders or research-peptide sellers in the past two years.
• Is the lab itself trustworthy? Is Janoshik testing legit? An audit of the lab and its data — internal-consistency check on the third-party-lab most cited by the niche.

All free, no signup, no ads. Reporters covering buyer-side stories can refer readers directly to these.

• /tools/coa-verifier — paste a Janoshik or Ascension test ID, instantly cross-check it against the mirrored corpus. Catches edited certificates and wrong-batch substitutions.
• /peptides-index — daily-refreshed cross-vendor pricing comparison across 5 active vendors and 8 compounds. Shows per-mg cost, in-stock flags, and last-walked timestamps.
• /janoshik — public hub for the third-party-lab corpus. Aggregate purity stats, region distribution, top-tested compounds, FAQ.
• /peptides/{compound} — per-compound guide with vendor purity leaderboard built from the public corpus.

vialaudit is editorially independent. Findings published on the site are not affected by affiliate relationships. The methodology page at vialaudit.com/methodology documents how audits are run, what disqualifies a vendor, the editorial firewall between revenue and findings, and the corrections process.

Some links on the site are cloaked affiliate redirects (/go/{vendor}) marked rel="sponsored nofollow". Pricing displayed in the index is the vendor's listed catalog price regardless of affiliate status. The full disclosure lives at vialaudit.com/disclosure.

For interview requests, fact-checks, or background: press@vialaudit.com

For tips on vendors we should audit, reader evidence, or corrections to existing coverage: tips@vialaudit.com

For affiliate-program inquiries (separate from editorial): partnerships@vialaudit.com

General: info@vialaudit.com

LinkedIn: linkedin.com/company/vialaudit — page updates, launch announcements, occasional findings.